EP0931138A4 - Method of producing a thymic microenvironment that supports the development of dendritic cells - Google Patents

Method of producing a thymic microenvironment that supports the development of dendritic cells

Info

Publication number
EP0931138A4
EP0931138A4 EP97910881A EP97910881A EP0931138A4 EP 0931138 A4 EP0931138 A4 EP 0931138A4 EP 97910881 A EP97910881 A EP 97910881A EP 97910881 A EP97910881 A EP 97910881A EP 0931138 A4 EP0931138 A4 EP 0931138A4
Authority
EP
European Patent Office
Prior art keywords
supports
development
producing
dendritic cells
thymic microenvironment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97910881A
Other languages
German (de)
French (fr)
Other versions
EP0931138A1 (en
Inventor
Barton F Haynes
Dhavalkumar D Patel
Clayton A Smith
G Diego Miralles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of EP0931138A1 publication Critical patent/EP0931138A1/en
Publication of EP0931138A4 publication Critical patent/EP0931138A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/065—Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides, bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1185—Thymus cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP97910881A 1996-10-10 1997-10-10 Method of producing a thymic microenvironment that supports the development of dendritic cells Withdrawn EP0931138A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3144596P 1996-10-10 1996-10-10
US31445P 1996-10-10
PCT/US1997/018317 WO1998015615A1 (en) 1996-10-10 1997-10-10 Method of producing a thymic microenvironment that supports the development of dendritic cells

Publications (2)

Publication Number Publication Date
EP0931138A1 EP0931138A1 (en) 1999-07-28
EP0931138A4 true EP0931138A4 (en) 2003-04-09

Family

ID=21859507

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97910881A Withdrawn EP0931138A4 (en) 1996-10-10 1997-10-10 Method of producing a thymic microenvironment that supports the development of dendritic cells

Country Status (5)

Country Link
EP (1) EP0931138A4 (en)
JP (1) JP2001503976A (en)
AU (1) AU4814997A (en)
CA (1) CA2268284A1 (en)
WO (1) WO1998015615A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO723097A0 (en) * 1997-06-06 1997-07-03 Australian National University, The A method for culturing cells
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
JP2002509716A (en) 1998-03-31 2002-04-02 ユニバーシティ テクノロジー コーポレイション Methods and compositions for raising an immune response to a telomerase antigen
CA2326819A1 (en) * 1998-04-24 1999-11-04 Transkaryotic Therapies, Inc. Delivery of therapeutic proteins via implantation of genetically modified cells in the omentum
US7351546B2 (en) 1998-09-22 2008-04-01 Becton, Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
US6495333B1 (en) 1998-09-22 2002-12-17 Becton Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
US6348050B1 (en) * 1999-04-30 2002-02-19 Medtronic, Inc. Infusion systems for creating microenvironments in a living body
AU2003233271A1 (en) * 2002-06-14 2003-12-31 Norwood Immunology Ltd Thymic epithelial cells with progenitor capacity
SG11201603166UA (en) 2013-10-24 2016-05-30 Ospedale San Raffaele Srl Method

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BARCENA ALICIA ET AL: "Lymphoid and myeloid differentiation of fetal liver CD34+ lineage- cells in human thymic organ culture.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 180, no. 1, 1994, pages 123 - 132, XP009001778, ISSN: 0022-1007 *
GALY A H M ET AL: "UNTRANSFECTED AND SV40-TRANSFECTED FETAL AND POSTNATAL HUMAN THYMIC STROMAL CELLS ANALYSIS OF PHENOTYPE, CYTOKINE GENE EXPRESSION AND CYTOKINE PRODUCTION", THYMUS, ELSEVIER, AMTERDAM,, NL, vol. 22, no. 1, 1993, pages 13 - 33, XP001038285, ISSN: 0165-6090 *
PAGLIA PAOLA ET AL: "Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 183, no. 1, 1996, pages 317 - 322, XP009000289, ISSN: 0022-1007 *
See also references of WO9815615A1 *
SHORTMAN K ET AL: "Thymic dendritic cells: surface phenotype, developmental origin and function.", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. UNITED STATES 1995, vol. 378, 1995, pages 21 - 29, XP009001777, ISSN: 0065-2598 *
TSAO SAI-WAH ET AL: "Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs).", EXPERIMENTAL CELL RESEARCH, vol. 218, no. 2, 1995, pages 499 - 507, XP002222454, ISSN: 0014-4827 *

Also Published As

Publication number Publication date
CA2268284A1 (en) 1998-04-16
WO1998015615A1 (en) 1998-04-16
EP0931138A1 (en) 1999-07-28
AU4814997A (en) 1998-05-05
JP2001503976A (en) 2001-03-27

Similar Documents

Publication Publication Date Title
IL127912A0 (en) Method of activating dendritic cells
GB2330253B (en) Connecting plate for battery holder and method of producing the same
HU9700851D0 (en) Method for producing l-lysin
IL129694A0 (en) Method for rupturing microalgae cells
GB9502022D0 (en) A method for preparing lymphohaematopoietic progenitor cells
EP1016643A4 (en) Method of producing methanol
EP0757968A4 (en) Hydrogen generator
HUP9901773A3 (en) Lower-energy hydrogen methods and structures
EP0807783A4 (en) Compound cell structure and method for producing the same
ZA97367B (en) A method of preparing the enantiomers of o-demethyltramadol
EP1100136A4 (en) Cell and method of producing the same
EP0931138A4 (en) Method of producing a thymic microenvironment that supports the development of dendritic cells
HU9601792D0 (en) Sealed connection produced by set in radially
IL128512A (en) Method for immortalizing cells
EP1050909A4 (en) Solar cell device and method of producing the same
HUP0001596A3 (en) Method for producing 5-aminomethyl-2-chloropyridines
GB2312960B (en) Electrochemical process
GB9620148D0 (en) Gravity producing system
GB9517227D0 (en) Wind generator
HUP0003768A3 (en) Method for producing thiochloroformates
AU131351S (en) Stamper
HUP0100505A3 (en) Method for producing chlorobenzoxazolene
IL132968A0 (en) Method for producing 2-cyclododecyl-1-propanol
HU9801666D0 (en) Process for producing cyanoformate esters
HK1018359A1 (en) Method for manufacturing the expanded grid of the storage battery

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990421

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 5/06 B

Ipc: 7A 01N 65/00 B

Ipc: 7A 01N 63/00 B

Ipc: 7C 12N 5/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030221

17Q First examination report despatched

Effective date: 20030829

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040311

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1018708

Country of ref document: HK